instruction stringlengths 459 733 | output stringclasses 181
values |
|---|---|
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Quality Assurance Team,
I am writing on behalf of a patient under my care who was started on Product A at a dose of 5mg. The patient has been taking this medication faithfully for approximately one month. Over the past two weeks, the patient began experiencin... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
To whom it may concern,
A sixty-two-year-old patient in my clinic was prescribed Product A 250mg and began therapy eight weeks ago. Initially the treatment appeared well tolerated, but the patient recently presented with concerning constipation. The onset was gradu... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Adverse Event Involving Product A
BODY:
Dear Support,
We are reporting a potential adverse reaction associated with Product A. The patient was maintained on 250mg for a duration of twelve months before developing acute-onset back pain. The event was severe enough to require an unscheduled clinic visit... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear Regulatory Team,
I am contacting you regarding a patient who initiated Product A therapy at 5mg approximately six months ago. The patient initially reported mild fatigue but more recently developed persistent and debilitating memory loss. The symptom severity has esc... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Medical Affairs,
This correspondence is to notify you of an undesirable medical occurrence linked to Product A exposure. The affected individual was receiving 2g for a period of four weeks when they began to experience anxiety. The patient describes the symptom as d... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear MedInfo,
I am a general practitioner writing to report what I believe is a significant adverse event associated with Product A. My patient, who has been compliant with 2g for fourteen days, presented today with pronounced back pain. The patient was previously healthy... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Pharmacovigilance Team,
We wish to place on record an adverse event report involving Product A 2g. The patient in question completed four months of continuous therapy before reporting distressing injection site redness. The reaction was unexpected given the e... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Medical Information Team,
As the attending physician for a long-term care facility, I am documenting an adverse reaction to Product A. A resident was started on 1g and after three months of treatment began to show signs of difficulty swallowing. The nursing staff no... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Dear Sales Team,
I am reaching out from a community health center to report a safety concern with Product A. A patient under our monitoring program for chronic therapy was maintained on 20mg for twenty-one days before developing acute ear pain. The reaction was suf... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Dear Medical Affairs,
This message serves as an adverse event notification for your pharmacovigilance records. A patient prescribed Product A at 5mg has developed persistent peripheral swelling following ten days of uninterrupted therapy. The patient has no concurr... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Safety Signal: Product A Related Event
BODY:
Dear Support,
I am the prescribing oncologist for a patient currently enrolled in supportive care with Product A 10mg. After completing six months of the prescribed regimen, the patient began experiencing insomnia that has proven refractory to standard symptomatic ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Commercial Operations,
A pediatric patient under our supervision was recently started on Product A at 10mg. The parents report that approximately eight months into therapy, the child began exhibiting neck stiffness that was not present at baseline. The symptoms have... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Medical Affairs,
I am writing from a tertiary referral hospital to report a suspected adverse reaction to Product A. The patient had been stable on 1g for twenty-one days before an abrupt presentation of allergic reaction during routine follow-up. The clinica... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Adverse Event Involving Product A
BODY:
To whom it may concern,
This adverse event report concerns a patient enrolled in our outpatient cardiology clinic who was prescribed Product A 200mg. The patient tolerated the initial phase well, but after approximately four weeks began to complain of sore throa... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Hello,
I am a rheumatology specialist reporting an adverse drug reaction involving Product A. The affected patient was receiving 250mg as part of a combination regimen when, after three months of exposure, they developed significant loss of consciousness. The reaction ap... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear Quality Assurance Team,
From the neurology department, we are documenting a safety signal with Product A. A patient with a previously stable neurological profile was commenced on 20mg and after eight months began reporting muscle weakness that has progressively affec... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
To whom it may concern,
I manage a busy family practice and am reporting what appears to be an adverse event linked to Product A 250mg. The patient is generally healthy with no significant medical history and had been taking the medication as directed for two week... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Medical Affairs,
As a clinical pharmacist in a large hospital system, I am forwarding an adverse event report involving Product A. The patient was receiving 100mg per protocol for fourteen days before presenting with itching during a scheduled infusion visit. The in... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Medical Information Team,
I am contacting you from a dialysis center where a patient receiving Product A at 500mg has developed concerning fainting spells after six months of treatment. The presentation is unusual in this population and has required modificat... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Hello,
This message documents an adverse event in a geriatric patient prescribed Product A 5mg. The patient resides in an assisted living facility and the nursing staff observed high fever emerging after three weeks of therapy. The presentation was initially subtle... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Quality Assurance Team,
I am writing on behalf of a patient under my care who was started on Product A at a dose of 200mg. The patient has been taking this medication faithfully for approximately one month. Over the past two weeks, the patient began experiencing blo... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Medical Affairs,
A sixty-two-year-old patient in my clinic was prescribed Product A 10mg and began therapy four weeks ago. Initially the treatment appeared well tolerated, but the patient recently presented with concerning anxiety. The onset was gradual but h... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Medical Information Team,
We are reporting a potential adverse reaction associated with Product A. The patient was maintained on 5mg for a duration of twenty-one days before developing acute-onset loss of consciousness. The event was severe enough to require an unsc... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Dear Regulatory Team,
I am contacting you regarding a patient who initiated Product A therapy at 100mg approximately twelve months ago. The patient initially reported mild fatigue but more recently developed persistent and debilitating rapid weight loss. The sympto... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Hi,
This correspondence is to notify you of an undesirable medical occurrence linked to Product A exposure. The affected individual was receiving 50mg for a period of eight months when they began to experience back pain. The patient describes the symptom as distre... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Hello,
I am a general practitioner writing to report what I believe is a significant adverse event associated with Product A. My patient, who has been compliant with 200mg for twelve months, presented today with pronounced neck stiffness. The patient was previously health... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Hello,
We wish to place on record an adverse event report involving Product A 1g. The patient in question completed ten days of continuous therapy before reporting distressing wheezing. The reaction was unexpected given the established safety profile at this dosage... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Medical Information Team,
As the attending physician for a long-term care facility, I am documenting an adverse reaction to Product A. A resident was started on 100mg and after four weeks of treatment began to show signs of ear pain. The nursing staff noted a clear ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Support,
I am reaching out from a community health center to report a safety concern with Product A. A patient under our monitoring program for chronic therapy was maintained on 2g for four weeks before developing acute muscle pain. The reaction was sufficiently sev... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Regulatory Team,
This message serves as an adverse event notification for your pharmacovigilance records. A patient prescribed Product A at 5mg has developed persistent menstrual irregularities following four months of uninterrupted therapy. The patient has no concu... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
To whom it may concern,
I am the prescribing oncologist for a patient currently enrolled in supportive care with Product A 500mg. After completing two months of the prescribed regimen, the patient began experiencing hair loss that has proven refractory to standard... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Adverse Event Involving Product A
BODY:
Dear MedInfo,
A pediatric patient under our supervision was recently started on Product A at 50mg. The parents report that approximately three weeks into therapy, the child began exhibiting dizziness that was not present at baseline. The symptoms have persisted ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Hi,
I am writing from a tertiary referral hospital to report a suspected adverse reaction to Product A. The patient had been stable on 500mg for three months before an abrupt presentation of excessive sweating during routine follow-up. The clinical team has ruled out infe... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Dear Support,
This adverse event report concerns a patient enrolled in our outpatient cardiology clinic who was prescribed Product A 5mg. The patient tolerated the initial phase well, but after approximately eight months began to complain of severe abdominal pain t... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Medical Affairs,
I am a rheumatology specialist reporting an adverse drug reaction involving Product A. The affected patient was receiving 10mg as part of a combination regimen when, after three months of exposure, they developed significant erectile dysfunct... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Hi,
From the neurology department, we are documenting a safety signal with Product A. A patient with a previously stable neurological profile was commenced on 100mg and after twelve months began reporting ear pain that has progressively affected functional independence. N... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear Medical Affairs,
I manage a busy family practice and am reporting what appears to be an adverse event linked to Product A 50mg. The patient is generally healthy with no significant medical history and had been taking the medication as directed for twenty-one days. Th... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Medical Information Team,
As a clinical pharmacist in a large hospital system, I am forwarding an adverse event report involving Product A. The patient was receiving 10mg per protocol for two months before presenting with skin discoloration during a scheduled infusi... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear Quality Assurance Team,
I am contacting you from a dialysis center where a patient receiving Product A at 200mg has developed concerning blurred vision after six weeks of treatment. The presentation is unusual in this population and has required modification of the d... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Commercial Operations,
This message documents an adverse event in a geriatric patient prescribed Product A 250mg. The patient resides in an assisted living facility and the nursing staff observed bad taste in mouth emerging after two months of therapy. The presentat... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Hello,
I am writing on behalf of a patient under my care who was started on Product A at a dose of 1g. The patient has been taking this medication faithfully for approximately eight weeks. Over the past two weeks, the patient began experiencing high blood sugar th... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Sales Team,
A sixty-two-year-old patient in my clinic was prescribed Product A 10mg and began therapy fourteen days ago. Initially the treatment appeared well tolerated, but the patient recently presented with concerning shortness of breath. The onset was gradual bu... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear Medical Information Team,
We are reporting a potential adverse reaction associated with Product A. The patient was maintained on 10mg for a duration of fourteen days before developing acute-onset ear pain. The event was severe enough to require an unscheduled clinic ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Quality Assurance Team,
I am contacting you regarding a patient who initiated Product A therapy at 100mg approximately two months ago. The patient initially reported mild fatigue but more recently developed persistent and debilitating anxiety. The symptom severity h... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Sales Team,
This correspondence is to notify you of an undesirable medical occurrence linked to Product A exposure. The affected individual was receiving 50mg for a period of fourteen days when they began to experience wheezing. The patient describes the symptom as ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Hello,
I am a general practitioner writing to report what I believe is a significant adverse event associated with Product A. My patient, who has been compliant with 2g for one month, presented today with pronounced sore throat. The patient was previously healthy with no... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Sales Team,
We wish to place on record an adverse event report involving Product A 250mg. The patient in question completed six months of continuous therapy before reporting distressing skin discoloration. The reaction was unexpected given the established safety pro... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Hi,
As the attending physician for a long-term care facility, I am documenting an adverse reaction to Product A. A resident was started on 200mg and after two months of treatment began to show signs of hearing loss. The nursing staff noted a clear temporal pattern linkin... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear Sales Team,
I am reaching out from a community health center to report a safety concern with Product A. A patient under our monitoring program for chronic therapy was maintained on 10mg for six weeks before developing acute sore throat. The reaction was sufficiently ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Medical Affairs,
This message serves as an adverse event notification for your pharmacovigilance records. A patient prescribed Product A at 2g has developed persistent high blood sugar following twelve months of uninterrupted therapy. The patient has no concurrent m... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear Commercial Operations,
I am the prescribing oncologist for a patient currently enrolled in supportive care with Product A 200mg. After completing six weeks of the prescribed regimen, the patient began experiencing frequent urination that has proven refractory to stan... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Sales Team,
A pediatric patient under our supervision was recently started on Product A at 1g. The parents report that approximately six weeks into therapy, the child began exhibiting dry mouth that was not present at baseline. The symptoms have persisted des... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear Medical Affairs,
I am writing from a tertiary referral hospital to report a suspected adverse reaction to Product A. The patient had been stable on 20mg for two weeks before an abrupt presentation of severe fatigue during routine follow-up. The clinical team has rule... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Sales Team,
This adverse event report concerns a patient enrolled in our outpatient cardiology clinic who was prescribed Product A 1g. The patient tolerated the initial phase well, but after approximately eight months began to complain of insomnia that worsen... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Dear Quality Assurance Team,
I am a rheumatology specialist reporting an adverse drug reaction involving Product A. The affected patient was receiving 200mg as part of a combination regimen when, after four weeks of exposure, they developed significant abnormal ble... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Pharmacovigilance Team,
From the neurology department, we are documenting a safety signal with Product A. A patient with a previously stable neurological profile was commenced on 200mg and after four weeks began reporting abnormal bleeding that has progressively aff... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Safety Signal: Product A Related Event
BODY:
Dear Pharmacovigilance Team,
I manage a busy family practice and am reporting what appears to be an adverse event linked to Product A 20mg. The patient is generally healthy with no significant medical history and had been taking the medication as directed for two m... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Hi,
As a clinical pharmacist in a large hospital system, I am forwarding an adverse event report involving Product A. The patient was receiving 1g per protocol for twelve months before presenting with nausea during a scheduled infusion visit. The infusion was immed... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Dear Commercial Operations,
I am contacting you from a dialysis center where a patient receiving Product A at 20mg has developed concerning facial swelling after six months of treatment. The presentation is unusual in this population and has required modification o... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear Quality Assurance Team,
This message documents an adverse event in a geriatric patient prescribed Product A 5mg. The patient resides in an assisted living facility and the nursing staff observed insomnia emerging after six months of therapy. The presentation was init... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Partner Relations,
I am writing on behalf of a patient under my care who was started on Product A at a dose of 10mg. The patient has been taking this medication faithfully for approximately four months. Over the past two weeks, the patient began experiencing chest t... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Quality Assurance Team,
A sixty-two-year-old patient in my clinic was prescribed Product A 50mg and began therapy three months ago. Initially the treatment appeared well tolerated, but the patient recently presented with concerning allergic reaction. The onset was g... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear Medical Information Team,
We are reporting a potential adverse reaction associated with Product A. The patient was maintained on 10mg for a duration of six months before developing acute-onset agitation. The event was severe enough to require an unscheduled clinic vi... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear Pharmacovigilance Team,
I am contacting you regarding a patient who initiated Product A therapy at 10mg approximately two months ago. The patient initially reported mild fatigue but more recently developed persistent and debilitating excessive sweating. The symptom s... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Hi,
This correspondence is to notify you of an undesirable medical occurrence linked to Product A exposure. The affected individual was receiving 5mg for a period of two months when they began to experience vomiting. The patient describes the symptom as distressing and u... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Safety Signal: Product A Related Event
BODY:
Dear Commercial Operations,
I am a general practitioner writing to report what I believe is a significant adverse event associated with Product A. My patient, who has been compliant with 200mg for ten days, presented today with pronounced excessive sweating. The pa... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Hello,
We wish to place on record an adverse event report involving Product A 10mg. The patient in question completed four months of continuous therapy before reporting distressing unexplained bruising. The reaction was unexpected given the established safety profile at t... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Sales Team,
As the attending physician for a long-term care facility, I am documenting an adverse reaction to Product A. A resident was started on 250mg and after one month of treatment began to show signs of injection site pain. The nursing staff noted a clear temp... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
To whom it may concern,
I am reaching out from a community health center to report a safety concern with Product A. A patient under our monitoring program for chronic therapy was maintained on 200mg for three weeks before developing acute erectile dysfunction. The reactio... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Safety Signal: Product A Related Event
BODY:
Dear Commercial Operations,
This message serves as an adverse event notification for your pharmacovigilance records. A patient prescribed Product A at 10mg has developed persistent skin rash following four months of uninterrupted therapy. The patient has no concurr... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear MedInfo,
I am the prescribing oncologist for a patient currently enrolled in supportive care with Product A 20mg. After completing three weeks of the prescribed regimen, the patient began experiencing skin rash that has proven refractory to standard symptomatic manag... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear Medical Affairs,
A pediatric patient under our supervision was recently started on Product A at 250mg. The parents report that approximately eight months into therapy, the child began exhibiting burning urination that was not present at baseline. The symptoms have pe... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Hello,
I am writing from a tertiary referral hospital to report a suspected adverse reaction to Product A. The patient had been stable on 200mg for six months before an abrupt presentation of muscle pain during routine follow-up. The clinical team has ruled out inf... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Pharmacovigilance Team,
This adverse event report concerns a patient enrolled in our outpatient cardiology clinic who was prescribed Product A 250mg. The patient tolerated the initial phase well, but after approximately twenty-one days began to complain of burning u... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Clinical Safety Alert: Product A
BODY:
Dear Medical Affairs,
I am a rheumatology specialist reporting an adverse drug reaction involving Product A. The affected patient was receiving 200mg as part of a combination regimen when, after one month of exposure, they developed significant skin rash. The reaction ap... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Hello,
From the neurology department, we are documenting a safety signal with Product A. A patient with a previously stable neurological profile was commenced on 250mg and after three weeks began reporting memory loss that has progressively affected functional inde... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Dear Partner Relations,
I manage a busy family practice and am reporting what appears to be an adverse event linked to Product A 1g. The patient is generally healthy with no significant medical history and had been taking the medication as directed for three months... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Partner Relations,
As a clinical pharmacist in a large hospital system, I am forwarding an adverse event report involving Product A. The patient was receiving 10mg per protocol for three weeks before presenting with slurred speech during a scheduled infusion visit. ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Hi,
I am contacting you from a dialysis center where a patient receiving Product A at 200mg has developed concerning injection site pain after six months of treatment. The presentation is unusual in this population and has required modification of the dialysis pres... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "97%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Adverse Event Involving Product A
BODY:
To whom it may concern,
This message documents an adverse event in a geriatric patient prescribed Product A 50mg. The patient resides in an assisted living facility and the nursing staff observed headache emerging after ten days of therapy. The presentation was ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Drug Reaction: Product A
BODY:
Dear Sales Team,
I am writing on behalf of a patient under my care who was started on Product A at a dose of 250mg. The patient has been taking this medication faithfully for approximately eight months. Over the past two weeks, the patient began experiencing dark urine t... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
To whom it may concern,
A sixty-two-year-old patient in my clinic was prescribed Product A 500mg and began therapy two months ago. Initially the treatment appeared well tolerated, but the patient recently presented with concerning tingling sensation. The onset was... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Dear Sales Team,
We are reporting a potential adverse reaction associated with Product A. The patient was maintained on 20mg for a duration of four weeks before developing acute-onset erectile dysfunction. The event was severe enough to require an unscheduled clini... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "90%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear MedInfo,
I am contacting you regarding a patient who initiated Product A therapy at 20mg approximately four weeks ago. The patient initially reported mild fatigue but more recently developed persistent and debilitating muscle pain. The symptom severity has escalated... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Dear Support,
This correspondence is to notify you of an undesirable medical occurrence linked to Product A exposure. The affected individual was receiving 200mg for a period of six weeks when they began to experience loss of consciousness. The patient describes th... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Adverse Event Involving Product A
BODY:
Dear Quality Assurance Team,
I am a general practitioner writing to report what I believe is a significant adverse event associated with Product A. My patient, who has been compliant with 1g for three months, presented today with pronounced chest tightness. The ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Dear Partner Relations,
We wish to place on record an adverse event report involving Product A 5mg. The patient in question completed eight weeks of continuous therapy before reporting distressing mood swings. The reaction was unexpected given the established safety profi... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "98%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Urgent: Adverse Event Involving Product A
BODY:
Dear Regulatory Team,
As the attending physician for a long-term care facility, I am documenting an adverse reaction to Product A. A resident was started on 200mg and after twelve months of treatment began to show signs of skin rash. The nursing staff noted a cl... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Partner Relations,
I am reaching out from a community health center to report a safety concern with Product A. A patient under our monitoring program for chronic therapy was maintained on 500mg for six months before developing acute dark urine. The reaction was suff... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Event Report: Product A
BODY:
Hi,
This message serves as an adverse event notification for your pharmacovigilance records. A patient prescribed Product A at 200mg has developed persistent chills following six weeks of uninterrupted therapy. The patient has no concurrent medical conditions that would i... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Support,
I am the prescribing oncologist for a patient currently enrolled in supportive care with Product A 20mg. After completing four weeks of the prescribed regimen, the patient began experiencing blood in stool that has proven refractory to standard sympt... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Safety Signal: Product A Related Event
BODY:
Dear Medical Affairs,
A pediatric patient under our supervision was recently started on Product A at 20mg. The parents report that approximately three months into therapy, the child began exhibiting sore throat that was not present at baseline. The symptoms have pe... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "93%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Hi,
I am writing from a tertiary referral hospital to report a suspected adverse reaction to Product A. The patient had been stable on 10mg for two months before an abrupt presentation of excessive thirst during routine follow-up. The clinical team has ruled out infectiou... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "99%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Patient Safety Notification: Product A
BODY:
Dear Medical Affairs,
This adverse event report concerns a patient enrolled in our outpatient cardiology clinic who was prescribed Product A 100mg. The patient tolerated the initial phase well, but after approximately six months began to complain of slurred speech ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "94%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Suspected Adverse Reaction to Product A
BODY:
Dear Regulatory Team,
I am a rheumatology specialist reporting an adverse drug reaction involving Product A. The affected patient was receiving 50mg as part of a combination regimen when, after eight months of exposure, they developed significant slurred speech. T... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Pharmacovigilance Report for Product A
BODY:
Hello,
From the neurology department, we are documenting a safety signal with Product A. A patient with a previously stable neurological profile was commenced on 250mg and after two months began reporting fainting spells that has progressively affected functional i... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "96%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear MedInfo,
I manage a busy family practice and am reporting what appears to be an adverse event linked to Product A 2g. The patient is generally healthy with no significant medical history and had been taking the medication as directed for twelve months. The new onset ... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "92%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Medical Safety Notice: Product A
BODY:
Dear Regulatory Team,
As a clinical pharmacist in a large hospital system, I am forwarding an adverse event report involving Product A. The patient was receiving 5mg per protocol for six weeks before presenting with confusion during a scheduled infusion visit. The infusi... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "91%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Adverse Event Report: Product A
BODY:
Dear Regulatory Team,
I am contacting you from a dialysis center where a patient receiving Product A at 20mg has developed concerning light sensitivity after ten days of treatment. The presentation is unusual in this population and has required modification of the dialysi... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
SUBJECT: Safety Signal: Product A Related Event
BODY:
Dear Quality Assurance Team,
This message documents an adverse event in a geriatric patient prescribed Product A 500mg. The patient resides in an assisted living facility and the nursing staff observed confusion emerging after three weeks of therapy. The presentati... | {"Classification_of_request": {"Classification": "Adverse Event", "Confidence_percentage": "95%"}, "Analysis": "The email describes an undesirable medical occurrence experienced by a patient after using Product A, which qualifies as an Adverse Event."} |
End of preview. Expand in Data Studio
Ramesh10/medical-emails-classification-1000
Generated by ML Intern
This dataset repository was generated by ML Intern, an agent for machine learning research and development on the Hugging Face Hub.
- Try ML Intern: https://smolagents-ml-intern.hf.space
- Source code: https://github.com/huggingface/ml-intern
Usage
from datasets import load_dataset
dataset = load_dataset('Ramesh10/medical-emails-classification-1000')
- Downloads last month
- 6